News Releases

Product-related press releases will be removed from our website within three weeks after publication. Press releases are made available for the media and to comply with applicable rules and regulations they are removed from our website. Previous press releases can be provided upon request. Please contact us here.

June 5, 2023
Ascendis Pharma Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany
May 13, 2023
Ascendis Pharma Showcases Commitment to Rare Endocrine Diseases at the 25th European Congress of Endocrinology 2023
May 1, 2023
U.S. Food & Drug Administration Issues Complete Response Letter for TransCon™ PTH in Hypoparathyroidism
April 27, 2023
Ascendis Pharma Reports First Quarter 2023 Financial Results
Displaying 11 - 20 of 27